AlzeCure Pharma AB (publ) (ALZCUR.ST)

SEK 1.17

(0.0%)

Long Term Debt Summary of AlzeCure Pharma AB (publ)

  • AlzeCure Pharma AB (publ)'s latest annual long term debt in 2023 was - SEK , down 0.0% from previous year.
  • AlzeCure Pharma AB (publ)'s latest quarterly long term debt in 2024 Q2 was - SEK , down 0.0% from previous quarter.
  • AlzeCure Pharma AB (publ) reported annual long term debt of - SEK in 2022, down 0.0% from previous year.
  • AlzeCure Pharma AB (publ) reported annual long term debt of - SEK in 2021, down 0.0% from previous year.
  • AlzeCure Pharma AB (publ) reported quarterly long term debt of - SEK for 2024 Q1, down 0.0% from previous quarter.
  • AlzeCure Pharma AB (publ) reported quarterly long term debt of - SEK for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of AlzeCure Pharma AB (publ) (2023 - 2017)

Historical Annual Long Term Debt of AlzeCure Pharma AB (publ) (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 - SEK 0.0%
2022 - SEK 0.0%
2021 - SEK 0.0%
2020 - SEK 0.0%
2019 - SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%

Peer Long Term Debt Comparison of AlzeCure Pharma AB (publ)

Name Long Term Debt Long Term Debt Difference
AcuCort AB - SEK NaN%
BioGaia AB (publ) 26.35 Million SEK 100.0%
Enzymatica AB (publ) 24.88 Million SEK 100.0%
Enorama Pharma AB (publ) 303 Thousand SEK 100.0%
Gabather AB (publ) - SEK NaN%
Klaria Pharma Holding AB (publ.) - SEK NaN%
Moberg Pharma AB (publ) 3.46 Million SEK 100.0%
Nanexa AB (publ) 2.08 Million SEK 100.0%
Newbury Pharmaceuticals AB (publ) - SEK NaN%
ODI Pharma AB - SEK NaN%
Orexo AB (publ) 448.4 Million SEK 100.0%
Probi AB (publ) 38.21 Million SEK 100.0%
Swedencare AB (publ) 1.44 Billion SEK 100.0%
Swedish Orphan Biovitrum AB (publ) 11.35 Billion SEK 100.0%
Toleranzia AB 850 Thousand SEK 100.0%
Vivesto AB 5.18 Million SEK 100.0%